Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide in adolescents with type 2 diabetes
NCT00658021Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2008
- Primary completion
- Apr 2019
- Modality
- Peptides
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of exenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoints: Adjusted Change From Baseline in Glycated Hemoglobin A1c at 28 weeks and Number of Participants With Post-Treatment Adverse Events of Special Interest at 3 years. Started May 2008; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00658021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00658021.